Alembic debuts generic Faslodex
Fulvestrant injection is an estrogen receptor antagonist used to treat certain types of breast cancer.
Alembic is introducing Fulvestrant injection 250 mg/5ml, which is the generic of AstraZeneca’s Faslodex injection.
Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy and, HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
[Read more: Alembic intros generic Perforomist]
Alembic will supply Fulvestrant Injection in cartons of two single-dose 250 mg/5 ml prefilled syringes.